DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure...
- Mechanism
- Curator reviewed
DP-VPA is a new chemical entity (NCE) utilising D-Pharm's proprietary technology, Regulated Activation of Prodrugs (D-RAPTM). DP-VPA comprises VPA linked to a phospholipid moiety to form a prodrug that may be specifically cleaved by phospholipase A2 (PLA2), an enzyme specifically up-regulated in firing neurons. With a seizure imminent, VPA is preferentially released at the site of pathology until PLA2 hyperactivation subsides, enabling precise control over drug action.
- Primary indication
- Investigated for use/treatment in bipolar disorders, epilepsy, and migraine and cluster headaches.Curator reviewed
What you can answer from here — as of April 02, 2025
Which companies are running trials of DP-VPA, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account